Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4459887
Max Phase: Preclinical
Molecular Formula: C23H15ClFNO4S2
Molecular Weight: 487.96
Molecule Type: Unknown
Associated Items:
ID: ALA4459887
Max Phase: Preclinical
Molecular Formula: C23H15ClFNO4S2
Molecular Weight: 487.96
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C(c1ccc(-c2cccc(NS(=O)(=O)c3ccccc3)c2)s1)c1c(F)ccc(O)c1Cl
Standard InChI: InChI=1S/C23H15ClFNO4S2/c24-22-18(27)10-9-17(25)21(22)23(28)20-12-11-19(31-20)14-5-4-6-15(13-14)26-32(29,30)16-7-2-1-3-8-16/h1-13,26-27H
Standard InChI Key: XSBGMNVHRLMVIZ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 487.96 | Molecular Weight (Monoisotopic): 487.0115 | AlogP: 5.95 | #Rotatable Bonds: 6 |
Polar Surface Area: 83.47 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 7.17 | CX Basic pKa: | CX LogP: 5.92 | CX LogD: 5.43 |
Aromatic Rings: 4 | Heavy Atoms: 32 | QED Weighted: 0.33 | Np Likeness Score: -1.36 |
1. Abdelsamie AS, Herath S, Biskupek Y, Börger C, Siebenbürger L, Salah M, Scheuer C, Marchais-Oberwinkler S, Frotscher M, Pohlemann T, Menger MD, Hartmann RW, Laschke MW, van Koppen CJ.. (2019) Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing., 62 (3): [PMID:30645111] [10.1021/acs.jmedchem.8b01493] |
Source(1):